🔎 Trials Near Me

Utama › Tumor Stroma Gastrointestinal › Tennessee

Kajian klinikal Tumor Stroma Gastrointestinal di Tennessee

7 kajian untuk Tumor Stroma Gastrointestinal sedang mencari peserta di lokasi di Tennessee.

Bandar di Tennessee

Teks kajian rasmi (Bahasa Inggeris)

A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib Therapy

  • GSK Investigational Site, Knoxville
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 5 Okt 2026 · NCT07218926

A Study to Investigate Velzatinib Compared With Imatinib in Adult Participants With Previously Untreated Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (StrateGIST Frontline)

  • GSK Investigational Site, Knoxville
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 5 Okt 2026 · NCT07585266

DESTINY-PANTUMOUR04

  • Research Site, Nashville
Mengambil pesertaKajian pemerhatian
Umur 18 hingga 130 · Semua jantina · Dikemas kini 25 Sep 2026 · NCT07124000

A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations

  • SCRI - TriStar Medical Group Children's Specialists, Nashville
  • SCRI Oncology Partners, Nashville
Mengambil pesertaFasa 2
Umur 8 ke atas · Semua jantina · Dikemas kini 27 Jul 2026 · NCT05503797

A Study of Ziftomenib in Combination With Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)

  • Sarah Cannon Research Institute, Nashville
  • Vanderbilt University Medical Center, Nashville
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 5 Feb 2026 · NCT06655246

A Master Protocol to Evaluate DCC-3009 in Gastrointestinal Stromal Tumor (GIST)

  • Vanderbilt University-Ingram Cancer Center, Nashville
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 5 Feb 2026 · NCT06630234

Daripada ClinicalTrials.gov, data diperoleh pada 6 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.